{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 8ad029d6-c61d-4f02-95c7-63a91ae2203d --><h2>Clarithromycin</h2><!-- end field 8ad029d6-c61d-4f02-95c7-63a91ae2203d -->","summary":"","htmlStringContent":"<!-- begin item e652d662-2d45-4d81-84d9-5ea7cfd4b5de --><!-- end item e652d662-2d45-4d81-84d9-5ea7cfd4b5de -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"79bea833-28dc-5d71-b274-5775873ee21b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ddbee24a-1b43-4566-b626-676e4d3657b7 --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field ddbee24a-1b43-4566-b626-676e4d3657b7 -->","summary":"","htmlStringContent":"<!-- begin item 0de6a2c9-7153-4b8e-becc-973688704178 --><!-- begin field 3796930e-a939-45f8-ba1e-8eab47fc0dd7 --><ul><li><strong>Do not prescribe clarithromycin to people with:</strong><ul><li>A history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes arrhythmias.</li><li>Hypokalaemia.</li><li>Severe hepatic impairment in combination with renal impairment.</li></ul></li><li><strong>Prescribe clarithromycin with caution</strong><strong> to:</strong><ul><li>People with:<ul><li>Impaired hepatic function and those taking potentially hepatotoxic drugs — clarithromycin is principally excreted by the liver. Hepatic dysfunction, including increased liver enzymes and cholestatic hepatitis (with or without jaundice), has been rarely reported with its use.</li><li>Conditions which predispose to QT interval prolongation (such as electrolyte disturbances) and those taking drugs that prolong the QT interval (such as amiodarone, sotalol, and amisulpride) — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes arrhythmias.</li><li>Chronic kidney disease (CKD) stages 4 and 5 — if the estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#managing-infection\">dose</a> of clarithromycin. Avoid Klaricid XL<sup>®</sup> or clarithromycin M/R preparations. </li><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (heart rate less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Myasthenia gravis — clarithromycin may aggravate symptoms.</li></ul></li><li>Pregnant or breastfeeding women. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/prescribing-information/clarithromycin/#use-in-pregnancy-breastfeeding\">Use in pregnancy and breastfeeding</a> for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 3796930e-a939-45f8-ba1e-8eab47fc0dd7 --><!-- end item 0de6a2c9-7153-4b8e-becc-973688704178 -->","subChapters":[]},{"id":"b569e417-9c12-5fee-b8cc-51dbcb7b37b7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 59a03326-77d9-4cdd-81cf-17dcbcf26847 --><h3>What are the possible adverse effects of clarithromycin?</h3><!-- end field 59a03326-77d9-4cdd-81cf-17dcbcf26847 -->","summary":"","htmlStringContent":"<!-- begin item f2fea3c3-e903-49e1-b558-b38e5a46e395 --><!-- begin field bb4b4662-bb4f-4f96-a55b-ff6a46061d2d --><ul><li><strong>The most common adverse effects of clarithromycin are </strong>abdominal pain, nausea, vomiting, taste perversion, and diarrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>].<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with clarithromycin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li></ul></li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can occur after large doses of clarithromycin.</li><li><strong>Other adverse effects of clarithromycin include:</strong><ul><li>Uncommon — burping, dry mouth, epistaxis, muscle complaints, oral disorders, thrombocytosis, and tremor.</li><li>Frequency not known — abnormal dreams, agranulocytosis, depersonalization, depression, mania, myopathy, psychotic disorder, renal failure, tooth discolouration, and urine discolouration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field bb4b4662-bb4f-4f96-a55b-ff6a46061d2d --><!-- end item f2fea3c3-e903-49e1-b558-b38e5a46e395 -->","subChapters":[]},{"id":"c1470174-271c-5c2a-a8df-6b542bc89f24","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f4f5ebc3-4ac4-4f08-a68d-ca243051e944 --><h3>What are some possible drug interactions with clarithromycin?</h3><!-- end field f4f5ebc3-4ac4-4f08-a68d-ca243051e944 -->","summary":"","htmlStringContent":"<!-- begin item 2dcc0210-03ba-4029-a447-adc32f2f993a --><!-- begin field b162ba8c-1604-4995-9b85-e4e3ea888a46 --><ul><li><strong>Drug interactions with clarithromycin include:</strong><ul><li><strong>Aminophylline</strong> — aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of Torsade de pointes) when given with clarithromycin.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li><strong>Calcium channel blockers</strong> — clarithromycin may increase serum levels of calcium channel blockers metabolized by CYP3A4 (such as verapamil, amlodipine, and diltiazem).<ul><li>Due to an increased risk of adverse effects, particularly hypotension, caution is advised with concurrent use.</li></ul></li><li><strong>Carbamazepine </strong>— clarithromycin slightly increases the concentration of carbamazepine. <ul><li>Monitor carbamazepine levels. </li><li>Advise the person to report symptoms of carbamazepine toxicity (such as nausea and vomiting, ataxia, and drowsiness).</li></ul></li><li><strong>Colchicine </strong>— clarithromycin possibly increases the risk of colchicine toxicity.<ul><li>Stop or reduce the dose of colchicine.</li><li>Avoid concurrent use in people with renal or hepatic impairment.</li></ul></li><li><strong>Digoxin</strong> — clarithromycin increases the concentration of digoxin.<ul><li>Monitor digoxin concentration.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, amisulpride, fluconazole, sildenafil, and tricyclic antidepressants) — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes.<ul><li>Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, and short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li><li><strong>Ergotamine </strong>— clarithromycin is predicted to increase the risk of ergotism when given with ergotamine. <ul><li>Concurrent use is contraindicated.</li></ul></li><li><strong>Oral hypoglycaemic drugs </strong>— clarithromycin is predicted to slightly increase the exposure to oral hypoglycaemic<strong> </strong>drugs (such as gliclazide, glibenclamide, glimepiride, and glipizide), increasing the risk of hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly, and adjust the dose of the oral hypoglycaemic<strong> </strong>drug accordingly. </li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy due to cytochrome P450 enzyme CYP3A4 inhibition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2014</a>].  <ul><li>For simvastatin (potent CYP3A4 inhibitor) — concurrent use is contraindicated. If clarithromycin treatment cannot be avoided, stop treatment with simvastatin during the course of antibiotic treatment.</li><li>For atorvastatin (moderate CYP3A4 inhibitor) — avoid concurrent use if possible. If clarithromycin treatment cannot be avoided, stop treatment with atorvastatin during the course of antibiotic treatment or prescribe the lowest starting dose of atorvastatin (that is 10 mg) and do not exceed 20 mg atorvastatin daily. Advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>For pravastatin — prescribe clarithromycin with caution, and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — rosuvastatin is not associated with cytochrome P450 interactions, and clinically significant interaction with clarithromycin is not expected for fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline </strong>— theophylline is predicted to cause hypokalaemia (potentially increasing the risk of Torsade de pointes) when given with clarithromycin.<ul><li>Monitor theophylline levels. Consider a dose reduction of theophylline if toxicity is suspected (for example if headache, nausea, or palpitations occur).</li></ul></li><li><strong>Quetiapine </strong>— clarithromycin may increase the plasma concentration of quetiapine.<ul><li>Avoid concurrent use.</li></ul></li><li><strong>Warfarin </strong>— clarithromycin may enhance the anticoagulant effect of warfarin. <ul><li>Increase monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. </li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after a course of clarithromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field b162ba8c-1604-4995-9b85-e4e3ea888a46 --><!-- end item 2dcc0210-03ba-4029-a447-adc32f2f993a -->","subChapters":[]},{"id":"a6bd775a-671a-522c-a404-f333f496c503","slug":"use-in-pregnancy-breastfeeding","fullItemName":"Use in pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 0bf07ae3-77bc-4fd2-a20b-aaa3009e3992 --><h3>Can clarithromycin be used during pregnancy and breastfeeding?</h3><!-- end field 0bf07ae3-77bc-4fd2-a20b-aaa3009e3992 -->","summary":"","htmlStringContent":"<!-- begin item 0211f26c-77df-4414-9dd9-aaa3009e394a --><!-- begin field 82a693f7-e2ed-4f12-bc2a-aaa3009e3992 --><ul><li><strong>Pregnancy</strong><ul><li>The manufacturer advises that the use of clarithromycin is not advised in pregnancy, particularly in the first trimester, unless the potential benefit outweighs the risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018b</a>].</li><li>Available data for clarithromycin does not suggest an increased risk of congenital malformation, but the possibility cannot be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">UKTIS, 2017a</a>].</li></ul></li><li><strong>Breastfeeding </strong><ul><li>Clarithromycin passes into breast milk.</li><li>The manufacturer states that the use of clarithromycin during breastfeeding is not advised unless the potential benefit outweighs the risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018b</a>].</li><li>Epidemiologic evidence indicates that the risk of hypertrophic pyloric stenosis in infants may be increased by use of maternal macrolides, especially in infants exposed in the first 2 weeks after birth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Fenner, 2016a</a>].</li></ul></li></ul><!-- end field 82a693f7-e2ed-4f12-bc2a-aaa3009e3992 --><!-- end item 0211f26c-77df-4414-9dd9-aaa3009e394a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}